Filtered By:
Source: Current Vascular Pharmacology
Condition: Thrombosis

This page shows you your search results in order of date. This is page number 4.

Order by Relevance | Date

Total 49 results found since Jan 2013.

Therapeutic Potential of Modulating microRNAs in Atherosclerotic Vascular Disease.
Abstract Atherosclerosis (also known as arteriosclerotic vascular disease) is a chronic inflammatory disease of the arterial wall, characterized by the formation of lipid-laden lesions. The activation of endothelial cells at atherosclerotic lesion-prone sites in the arterial tree results in the up-regulation of cell adhesion molecules and chemokines, which mediate the recruitment of circulating monocytes. Accumulation of monocytes and monocyte-derived phagocytes in the wall of large arteries leads to chronic inflammation and the development and progression of atherosclerosis. The lesion experiences the following s...
Source: Current Vascular Pharmacology - July 11, 2015 Category: Drugs & Pharmacology Authors: Araldi E, Chamorro-Jorganes A, van Solingen C, Fernandez-Hernando C, Suarez Y Tags: Curr Vasc Pharmacol Source Type: research

Primary Prevention of Ischaemic Stroke in Atrial Fibrillation: New Oral Anticoagulant Drugs for all?
Abstract Atrial fibrillation (AF) confers a 4.5% risk of stroke per year. The risk of stroke increases with various risk factors and until recently, warfarin has been the gold standard of thromboembolism prophylaxis in AF for many years. The dosage of warfarin requires regular adjustment dependent on the INR, to keep within a narrow therapeutic range of 2.0- 3.0. The INR can be altered by concomitant drugs, foods and alcohol and requires inconvenient blood monitoring. Underanticoagulation places patients at risk of stroke, whilst over-anticoagulation confers significant bleeding risk. Consequently approximately ha...
Source: Current Vascular Pharmacology - May 24, 2014 Category: Drugs & Pharmacology Authors: Foley J, Kirchhof P, Lip GY Tags: Curr Vasc Pharmacol Source Type: research

Acute antithrombotic treatment of ischemic stroke.
Abstract Antithrombotic medication is a cornerstone of acute ischemic stroke treatment and secondary prevention. The efficacy of thrombolysis with alteplase in acute stroke has been demonstrated in several clinical trials. This safe and costeffective therapy has transformed the practice of stroke care and has led to subsequent trials of other antithrombotic medications for treatment of ischemic stroke in the acute phase. These antithrombotics include thrombolytic, antiplatelet and anticoagulant agents. While, no other medication has yet demonstrated adequate efficacy, our current and evolving understanding of infa...
Source: Current Vascular Pharmacology - May 24, 2014 Category: Drugs & Pharmacology Authors: Alderazi YJ, Grotta JC Tags: Curr Vasc Pharmacol Source Type: research

Therapeutic Potential of Modulating microRNAs in Atherosclerotic Vascular Disease.
Abstract Atherosclerosis (also known as arteriosclerotic vascular disease) is a chronic inflammatory disease of the arterial wall, characterized by the formation of lipid-laden lesions. The activation of endothelial cells at atherosclerotic lesion-prone sites in the arterial tree results in the up-regulation of cell adhesion molecules and chemokines, which mediate the recruitment of circulating monocytes. Accumulation of monocytes and monocyte-derived phagocytes in the wall of large arteries leads to chronic inflammation and the development and progression of atherosclerosis. The lesion experiences the following s...
Source: Current Vascular Pharmacology - May 13, 2013 Category: Drugs & Pharmacology Authors: Araldi E, Chamorro-Jorganes A, Fernández-Hernando CV Tags: Curr Vasc Pharmacol Source Type: research